


**We claim:**

1. A compound having the structure of Formula I



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,  
5 diastereomers, polymorphs or N-oxides

wherein

m is an integer from 0-2;

**R<sub>1</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclalkyl;

- 10 **R<sub>2</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclalkyl, heteroarylalkyl, or heterocyclalkyl;

- R<sub>1</sub>** and **R<sub>2</sub>** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino,  
15 cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F, Cl, Br, I), aryl, aralkyl, heteroaryl, heterocyclalkyl, heteroarylalkyl or heterocyclalkyl;

**R<sub>3</sub>** can be NH<sub>2</sub>, NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or OR<sub>m</sub> (wherein R<sub>m</sub> can be hydrogen, alkyl, aralkyl, aryl, or metal ions (Na<sup>+</sup>, K<sup>+</sup>, Li<sup>+</sup>, Ca<sup>+</sup> or Mg<sup>+</sup>));

- 20 **R<sub>4</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclalkyl, heteroarylalkyl, heterocyclalkyl, -(CH<sub>2</sub>)<sub>1-4</sub>-O-R' (wherein R' can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclalkyl, or heteroarylalkyl), -C(=O)-R<sub>3</sub> (wherein R<sub>3</sub> is the same as defined above) -C(=O)R<sub>Z</sub> (wherein R<sub>Z</sub> is -NR<sub>7</sub>R<sub>8</sub> wherein R<sub>7</sub> and R<sub>8</sub> can be independently selected

- from hydrogen (provided that both  $R_7$  and  $R_8$  are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclalkyl,  $SO_2R_9$  (wherein  $R_9$  can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclalkyl); or  $R_7$  and  $R_8$  may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl; or
- ( $CH_2$ )<sub>1-4</sub> $NR_xR_y$  [wherein  $R_x$  and  $R_y$  can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl, heteroarylalkyl,  $-YR_u$  (wherein Y is C(=O), C(=S) or  $SO_2$  and  $R_u$  is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl or heteroarylalkyl),  $-C(=T)NR_u$  (wherein T is oxygen, sulphur,  $-CH(NO_2)$ ,  $-N(NO_2)$  or  $-N(CN)$  and  $R_u$  is the same as defined above) or  $-C(=O)OR_u$  (wherein  $R_u$  is the same as defined above)];

$R_5$  and  $R_6$  may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring.

2. A compound according to claim 1, wherein  $R_1$  is hydrogen or alkyl.
3. A compound according to claim 1, wherein  $R_1$  is hydrogen.
4. A compound of claim 1, wherein is  $R_1$  alkyl.
5. A compound according to claim 1, wherein  $R_1$  is methyl.
6. A compound according to claim 1, wherein  $R_2$  is hydrogen, aralkyl, heteroarylalkyl or aryl.
7. A compound according to claim 1, wherein  $R_2$  is hydrogen.
8. A compound according to claim 1, wherein  $R_2$  is optionally substituted aralkyl.
9. A compound according to claim 8, wherein the optional substituents on aralkyl are halo, hydroxy, alkynyloxy, aryl,  $-NHC(=O)R_9$ ,  $-OC(=O)R_9$  or  $-OCH_2R_9$ .

10. A compound according to claim 10, wherein the optional substituent on aralkyl is -NHC(=O)R<sub>9</sub> wherein R<sub>9</sub> is optionally substituted group selected from heteroaryl, heterocyclyl or aryl.
11. A compound according to claim 10, wherein R<sub>9</sub> is pyridyl, morpholinyl, methylpiperazinyl, bromopyridyl, phenyl, piperidinyl, difluorophenyl, dichlorophenyl, dichloropyridyl or methoxyphenyl.
12. A compound according to claim 9, wherein the optional substituent on aralkyl is -OC(=O)R<sub>9</sub> wherein R<sub>9</sub> is optionally substituted group selected from heterocyclyl.
13. A compound according to claim 12, wherein R<sub>9</sub> is morpholinyl, methylpiperazinyl.
14. A compound according to claim 9, wherein the optional substituent on aralkyl is -OCH<sub>2</sub>R<sub>9</sub> wherein R<sub>9</sub> is optionally substituted group is selected from aryl, heterocyclyl and alkynyl.
15. A compound according to claim 14, wherein R<sub>9</sub> is difluorophenyl, chlorophenyl, dichlorophenyl, piperidinyl, morpholinyl, methylpiperazinyl or propargyl.
16. A compound according to claim 1, wherein R<sub>2</sub> is heteroarylalkyl.
17. A compound according to claim 16, wherein R<sub>2</sub> is indolylmethyl.
18. A compound according to claim 1, wherein R<sub>2</sub> is aryl.
19. A compound according to claim 18, wherein R<sub>2</sub> is phenyl or benzodioxolyl.
20. A compound according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub> may also together join to form cyclic ring (3-8 membered), optionally benzofused containing 0-4 heteroatoms O, S or N.
21. A compound according to claim 20, wherein R<sub>1</sub> and R<sub>2</sub> together joins to form tetrahydroisoquinoline ring.
22. A compound according to claim 1, wherein R<sub>3</sub> is -OR<sub>m</sub> or -NH<sub>2</sub>.

23. A compound according to claim 22, wherein  $R_3$  is  $-OR_m$ .
24. A compound according to claim 23, wherein  $R_m$  is hydrogen, aralkyl or alkyl,
25. A compound according to claim 24, wherein  $R_m$  is hydrogen.
26. A compound according to claim 23, wherein  $R_m$  is alkyl or aralkyl.
- 5 27. A compound according to claim 26, wherein  $R_m$  is methyl, ethyl, butyl or tert-butyl.
28. A compound according to claim 22, wherein  $R_3$  is  $-NH_2$ .
29. A compound according to claim 1, wherein  $R_4$  is  $-C(=O)R_z$ , optionally substituted alkyl or  $-C(=O)R_3$ .
- 10 30. A compound according to claim 29, wherein  $R_4$  is  $-C(=O)R_z$ .
31. A compound according to claim 30, wherein  $R_z$  is  $-NR_7R_8$ .
32. A compound according to claim 31, wherein  $R_7$  is hydrogen, optionally substituted alkyl or heteroarylalkyl.
33. A compound according to claim 32, wherein  $R_7$  is hydrogen.
- 15 34. A compound according to claim 32, wherein  $R_7$  is optionally substituted alkyl.
35. A compound of claim 34, wherein  $R_7$  is hydroxymethyl or methyl.
36. A compound of claim 32, wherein  $R_7$  is heteroarylalkyl.
37. A compound of claim 36, wherein  $R_7$  is thiophenylmethyl.
38. A compound according to claim 31, wherein  $R_8$  is hydrogen or optionally  
20 substituted groups selected from aryl, aralkyl, heteroarylalkyl, cycloalkyl, alkyl, heterocyclalkyl, heterocycl, heteroaryl, alkenyl, alkynyl and alkoxy.
39. A compound of claim 38, wherein  $R_8$  is hydrogen.
40. A compound of claim 38, wherein  $R_8$  is optionally substituted aryl or aralkyl.

41. A compound of claim 40, wherein R<sub>8</sub> is chlorophenyl, dichlorophenyl, methoxyphenyl biphenyl, methylphenyl, fluorophenyl, diethylphenyl, isopropylphenyl, difluorophenyl, trifluoromethylphenyl, ethylphenyl, cyclopentyloxyphenyl, methoxybenzyl, dihydroindolyl, indolyl or benzodioxolyl.
- 5 42. A compound of claim 38, wherein R<sub>8</sub> is heteroarylalkyl or heteroaryl.
43. A compound of claim 42, wherein R<sub>8</sub> is thiophenylmethyl, thiazolyl, benzothiazolyl, pyridyl, thiadiazolylmethyl, indolylethyl, thiophenylethyl, pyridylmethyl, indolylethyl, methylthiadiazolyl, benzyl-tert-butyl-pyrazolyl, tolyl-tert-butyl-pyrazolyl, ethylsulphenylthiadiazolyl, dimethylthiazolyl or thiazolyl.
- 10 44. A compound of claim 38, wherein R<sub>8</sub> is optionally substituted heterocyclyl.
45. A compound of claim 44, wherein R<sub>8</sub> is methylpiperazinyl, methylpiperidinyl, piperidinyl or morpholinyl.
46. A compound of claim 38, wherein R<sub>8</sub> is optionally substituted cycloalkyl.
47. A compound of claim 46, wherein R<sub>8</sub> is cyclopropyl, cyclohexyl, adamantyl,  
15 cyclopentyl, hydroxycyclohexyl or cycloheptyl.
48. A compound of claim 38, wherein R<sub>8</sub> is optionally substituted alkyl, alkenyl or alkynyl.
49. A compound of claim 48, wherein R<sub>8</sub> is isopropyl, isobutyl, isopentyl, propenyl, propynyl, hydroxymethyl, hexyl or butyl.
- 20 50. A compound of claim 38, wherein R<sub>8</sub> is optionally substituted alkoxy.
51. A compound of claim 50, wherein R<sub>8</sub> is benzyloxy or methoxy.
52. A compound of claim 31, wherein R<sub>7</sub> and R<sub>8</sub> together joins to form an optionally substituted heterocyclic ring system.
53. A compound of claim 52, wherein R<sub>7</sub> and R<sub>8</sub> together joins to form  
25 methylpiperazinyl, benzyloxycarbonyl pyrrolidinyl, carboxypyrrolidinyl, dihydroindolyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, oxo-piperidinyl or piperazinyl.

54. A compound of claim 29, wherein  $R_4$  is optionally substituted alkyl selected from methyl.
55. A compound of claim 29, wherein  $R_4$  is  $-(CH_2)_{1-4}OR'$ .
56. A compound of claim 55, wherein  $R_4$  is hydroxymethyl, methoxymethyl or  
5 benzyloxymethyl.
57. A compound of claim 29, wherein  $R_4$  is  $-(CH_2)_{1-4}NR_xR_y$ .
58. A compound of claim 57, wherein  $R_4$  is methylenepyrrolidinyl.
59. A compound of claim 1, wherein  $R_4$  is  $-C(=O)R_3$ .
60. A compound claim 59, wherein  $R_3$  is  $-OR_m$ .
- 10 61. A compound of claim 60, wherein  $R_m$  is hydrogen or alkyl.
62. A compound of claim 61, wherein  $R_m$  is hydrogen.
63. A compound of claim 61, wherein  $R_m$  is alkyl.
64. A compound of claim 63, wherein  $R_m$  is ethyl.
65. A compound of claim 1, wherein  $R_5$  is hydrogen, alkyl or aryl.
- 15 66. A compound of claim 65, wherein  $R_5$  is hydrogen.
67. A compound of claim 65, wherein  $R_5$  is alkyl.
68. A compound of claim 67, wherein  $R_5$  is methyl.
69. A compound of claim 65, wherein  $R_5$  is aryl.
70. A compound of claim 69, wherein  $R_5$  is phenyl.
- 20 71. A compound of claim 1, wherein  $R_6$  is hydrogen.
72. A compound of claim 1, wherein  $R_6$  is alkyl.
73. A compound of claim 72, wherein  $R_6$  is methyl.

74. A compound of claim 1, wherein R<sub>6</sub> is aryl.
75. A compound of claim 74, wherein R<sub>6</sub> is phenyl.
76. A compound of claim 1, wherein m is 0 or 1.
77. A compound selected from
- 5 (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionic acid (Compound No. 1),
- (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 2),
- 10 (S)-3-(4-Benzoylamino-phenyl)-2-{{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 3),
- (S)-3-(4-Hydroxy-phenyl)-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 4),
- (S)-2-{{[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 5),
- 15 (S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound no. 6),
- (S)-3-(4-Benzoylamino-phenyl)-2-{{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7),
- 20 (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8),
- (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.10),
- 25 Lithium salt of (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No.11),
- Lithium salt of (S)-2-{{[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No.
- 30 12),
- Lithium salt of (S)-2-{{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionate (Compound No. 13),

- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14),
- Morpholine-4-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15),
- 5 4-Methyl-piperazine-1-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenylester (Compound No. 16),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 17),
- 10 (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 18),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(piperidine-4-carbonyl)-amino]-phenyl}-propionic-acid, salt with trifluoroacetic acid (Compound No.19),
- 15 (S)-2-{[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-3-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 20),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-2-carbonyl)-amino]-phenyl]-propionic-acid (Compound No. 21),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[6-bromo-pyridine-2-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 22),
- 20 (S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 23),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxyl-phenyl)-propionic acid (Compound No. 24),
- 25 (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-prop-2-ynyloxy-phenyl)-propionic-acid (Compound No. 27),
- 30 (S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 28),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-methoxy-benzyl-amino)-phenyl]-propionic acid (Compound No 29),
- 35 (S)-2-{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic-acid (Compound No. 30),



(S)-3-(4-(2,6-Dichlorobenzyloxy)-phenyl)-2-[(4R,5R)-5-[thiophen-2-yl-methyl]-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 31),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-phenyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (compound no 32),

5 (S)-2-[(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-[(pyridin-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No 33),

(S)-2-[(4S,5S)-5-(Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichlorobenzloxy-phenyl]-propionic acid (Compound No.34),

10 (4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No. 35),

Lithium salt of (S)-2-[(4R,5R)-5-Cyclopropyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionate (Compound No. 36),

(S)-2-[(4R,5R)-5-Cyclohexane-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No 37) ,

15 (S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-[(4R,5R)-5-(thiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 38) ,

(S)-2-[(4R,5R)-5-(Cyclopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No 39) ,

20 (S)-2-[(4R,5R)-5-Cyclohexyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 40),

(S)-2-[(4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbamoyl]-amino]-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 41) ,

(4R,5R)-5-[(S)-1-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 42) ,

25 (S)-3-(4-benzoylaminophenyl)-2-[(4R,5R)-5-(isopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 43),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid salt with trifluoroacetic acid (Compound No 44),

30 (S)-2-[(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic-acid (Compound No. 45),

(4R,5R)-5-[(S)-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46),

35 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-isopropylcarbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.47),

- (S)-2-[(4R,5R)-5-tert-Butyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(3-methyl-butylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 49),
- 5 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[(R)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 50),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[(S)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 51),
- 10 (S)-1-[(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-pyrrolidine-2-carboxylic acid benzyl ester (Compound No. 52),
- (S)-2-[(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 53),
- 15 (S)-2-[(4R,5R)-5-(Benzyloxy-carbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(morpholine-4-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 55),
- (S)-2-[(4R,5R)-5-(allyl-carbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56),
- 20 1-[(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-pyrrolidine-2-carboxylic acid (Compound No. 57),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[(tetrahydro-furan-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 58),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[2-(1H-indol-3-yl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 59),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[(2-thiophen-2-yl-ethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 60),
- 30 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[(pyridin-4-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 61),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(2,3-dihydro-indole-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 62),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(5-methyl-[1,3,4]thiadiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 63),
- 35 (S)-2-[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-3-(4-hydroxyphenyl)-propionic acid (Compound No. 64),

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(methyl-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No.65),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[methyl-(1-methyl-piperidine-4-yl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 66),
- 5 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 67),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(2-methoxy-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 68),
- 10 (S)-2-[(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69),
- (S)-2-[(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(3,5-dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic-acid (Compound No.71),
- 15 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(2,6-dichlorophenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 72),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-O-tolyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound no.73),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-dimethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-methyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75),
- (S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-methoxy-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic-acid (Compound No. 76),
- 25 (4R,5R)-5-[(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No.77),
- (S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic-acid (Compound No. 78),
- 30 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 79),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[(4R,5R)-5-(R)-3-hydroxy-pyrrolidine-1-carbonyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 80),
- 35 1-[(4R,5R)-5-[(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl]-pyrrolidine-2-carboxylic acid (Compound No. 81),

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(1-hydroxymethyl-propylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 82),
- 5 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-ethylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 83),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-prop-2-ynylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 84),
- 10 Trifluoroacetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2-morpholin-4-yl-ethylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 85),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 86),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 87),
- 15 (S)-2-[[[(4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88),
- (S)-2-[[[(4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 90)
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2-isopropyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 91),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2,6-difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 92),
- (S)-2-[[[(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-(4-[(pyridine-4-carbonyl)-amino]-phenyl)-propionic acid (Compound No. 93),
- 30 (S)-2-[[[(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-(4-[(pyridine-4-carbonyl)-amino]-phenyl)-propionic acid (Compound No. 94),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5S)-5-hydroxymethyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 95),
- (S)-2-[[[(4R,5R)-5-Carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 96),
- 35 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-((R)-2-hydrox-1-phenyl-ethylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 97),

- (S)-2-[[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98),
- (S)-2-[[[(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid  
5 (Compound No. 99),
- (S)-2-[[[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100),
- (S)-2-[[[(4R,5R)-5-Benzyloxymethyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101),
- 10 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2-trifluoromethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid  
(Compound No. 102),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(2-isopropoxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No.  
15 103),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(4-hydroxy-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 104),
- (S)-2-[[[(4R,5R)-5-Cyclopentylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 105),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-hexylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 106),
- (S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-[[[(4R,5R)-5-(3,4-dimethyl-isoxazol-5-ylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]amino]-propionic acid (Compound No. 107),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(pyridin-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 108),  
25
- {2-[[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-1,2,3,4-tetrahydro-isoquinoline]-3-carboxylic acid (Compound No. 109),
- 2-[[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-(1H-indol-3-yl)-propionic acid (Compound No. 110),
- 30 (S)-2-[[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 111),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[[(4R,5R)-5-(morpholin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 112),
- (S)-2-[[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113),  
35

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(4-hydroxy-cyclohexylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 114),
- 5 (S)-2-[[ (4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 115),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-heptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 116),
- 10 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(2-ethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 117),
- (4R,5R)-[1,3]Dioxolane-4,5-dicarboxylic acid-4-(((S)-1-carbamoyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl)-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118),
- (S)-2-[[ (4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid  
15 (Compound No. 119),
- (S)-2-[[ (4R,5R)-5-cycloheptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(5-ethylsulphanyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid  
20 (Compound No. 121),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (S)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 122),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(4,5-dimethylthiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 123),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (R)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 124),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(4-oxo-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 125),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl]-methyl-amino]-propionic acid (Compound No. 126),  
30
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(indan-5-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 127),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-phenethylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 128),
- 35 (S)-2-[[ (4R,5R)-5-[(Benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129),

- (S)-2-([(4R,5R)-5-Butylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 130),
- (S)-2-([(4R,5R)-5-(4-Acetyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 131),
- 5 (S)-2-([(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 132),
- (S)-2-([(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133),
- 10 3-Benzo[1,3]dioxol-5-yl-3-([(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 134),
- (S)-2-([(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-(2-methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135),
- (S)-2-([(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-(4-fluoro-phenyl)-propionic acid (Compound No. 136),
- 15 (S)-2-([(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-(2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137),
- (S)-3-([(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 138),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-([(4R,5R)-5-octylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 139),
- 3-([(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-(3,4-dimethoxy-benzyl)-amino]-propionic acid (Compound No. 140),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-([(4R,5S)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 141),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-([(4R,5R)-5-(3,5-dichloro-pyridin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 142),
- (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-([(4R,5R)-5-(2-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 143),
- 30 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-([(4R,5R)-5-[2-(1H-indol-3-yl)-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 144),
- (S)-2-([(4R,5R)-5-Cyclohexylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 145),
- 35

Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezoyloxy)-phenyl]-2-(((4R,5S)-5-pyrrolidin-1-ylmethyl-[1,3]Dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 146),

(S)-2-(((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147),

5 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-[(thiophen-2-ylmethyl)-carbonyl]-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 148),

(S)-3-[4-(2,6-Dichloro-benzoyloxy)-phenyl]-2-(((4R,5S)-2,2,5-trimethyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 149),

10 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(thiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 150),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(2-methoxy-benzylcarbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 151),

15 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 152),

(S)-2-(((4R,5R)-5-Cyclopropylcarbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 153), and

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(piperidin-1-ylcarbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 154).

20 78. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 together with pharmaceutically acceptable carrier, excipients or diluents.

79. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in  
25 an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable excipient.

80. A method of preventing, inhibiting or suppressing inflammatory condition in an  
30 animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1.


81. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma,





rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 79.

- 5 82. A method of preventing, inhibiting or suppressing inflammatory disease in an animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 78.



83. A method of preparing a compound of Formula XVI




- 10 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;




- condensing the compound of Formula III with a compound of Formula IV to yield a  
15 compound of Formula V;



hydrolyzing the compound of Formula V to yield a compound of Formula VI;




condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);




5 reducing the compound of Formula VIII to yield a compound of Formula XIII

(when R<sub>2</sub> is ) ;




reacting the compound of Formula XIII with a compound of Formula XIV to yield a compound of Formula XV; and




10



hydrolyzing the compound of Formula XIV to yield a compound of Formula XVI.





84. A method of preparing a compound of Formula XI




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;



condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




hydrolyzing the compound of Formula V to yield a compound of Formula VI;




Formula VI

condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);




Formula VII




Formula VIII

- 5 condensing the compound of Formula VIII with a compound of Formula IX to yield a compound of Formula X (when R<sub>2</sub> is *p*-CH<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-OH);




Formula IX




Formula X

hydrolyzing the compound of Formula X to yield a compound of Formula XI.




Formula XI

85. A method of preparing a compound of Formula XII




Formula XII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a  
5 compound of Formula II to yield a compound of Formula III;




Formula II




Formula III

condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




Formula IV




Formula V

10 hydrolyzing the compound of Formula V to yield a compound of Formula VI;




Formula VI


condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);



the compound of Formula VIII is hydrolyzed to yield a compound of Formula XII.




86. A method for preparing a compound of Formula XXI




5

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;




10


hydrolyzing the compound of Formula XVIII to yield a compound of Formula XIX;




condensing the compound of Formula XIX with a compound of Formula IV to furnish a compound of Formula XX; and






- 5 hydrolyzing the compound of Formula XX to yield a compound of Formula XXI.




87. A method for preparing a compound of Formula XXI




- 10 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;




hydrolyzing the compound of Formula XVIII to yield a compound of Formula XXII; and



condensing the compound of Formula XXIII with a compound of Formula IV to yield a  
5 compound of Formula XXI.






88. A method for preparing a compound of Formula XXIV




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,  
10 diastereomers, polymorphs or N-oxides wherein the method comprises condensing a  
compound of Formula III with a compound of Formula XVII to yield a compound of  
Formula XVIII;







reacting the compound of Formula XVIII with a compound of Formula IX (when  $R_2$  is p-hydroxy benzyl) to yield a compound of Formula XXIII; and




- 5 hydrolyzing the compound of Formula XXIII to yield a compound of Formula XXIV.



89. A method for preparation of compound of Formula XXVII




- 10 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




Formula XXV

to yield a compound of Formula XXVI (wherein P<sub>1</sub> is ethyl, t-butyl, or benzyl); and




Formula XXVI

hydrolyzing the compound of Formula XXVI to furnish a compound of Formula XXVII.




Formula XXVII

- 5 90. A method for preparation of compound of Formula XXIII



Formula XXIII


its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV



Formula XXV

to yield a compound of Formula XXVI (wherein  $P_1$  is ethyl, t-butyl, or benzyl); and


reacting the compound of Formula XXVI with a compound of Formula  $R_m\text{-hal}$  to yield a compound of Formula XXVIII; and



Formula XXVIII


5

hydrolyzing the compound of Formula XXVIII to yield a compound of Formula XXXIII.




Formula XXXIII

91. A method for preparation of compound of Formula XXXIV




Formula XXXIV

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




Formula XXV

- 5 to yield a compound of Formula XXVI (wherein P<sub>1</sub> is ethyl, t-butyl, or benzyl); and  
reacting the compound of Formula XXVI with a compound of Formula R<sub>m</sub>-hal to yield a compound of Formula XXIX; and



Formula XXIX


hydrolyzing the compound of Formula XXIX to yield a compound of Formula XXXIV.



Formula XXXIV


10

92. A method for preparation of compound of Formula XXXII



Formula XXXI

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




Formula XXV

5


to yield a compound of Formula XXVI (wherein P<sub>1</sub> is ethyl, t-butyl, or benzyl); and

reacting the compound of Formula XXVI with a compound of Formula L-hal to yield a compound of Formula XXX;




Formula XXX


- 10    condensing the compound of Formula XXX with a compound of Formula IV (wherein OL is a leaving group selected from, mesyl or tosyl) to yield a compound of Formula XXXI; and



hydrolyzing the compound of Formula XXXI to yield a compound of Formula XXXII.





93. A method for the preparation of the compound of Formula XXXVIII



5


its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises hydrolyzing a compound of Formula XXXV to yield a compound of Formula XXXVI;






Formula XXXVI

reacting the compound of Formula XXXVI with a compound of Formula VII to yield a compound of Formula XXXVII; and




Formula VII



Formula XXXVII



- 5 hydrolyzing the compound of Formula XXXIII to yield a compound of Formula XXXVIII.

94. A method for the preparation of the compound of Formula XL



Formula XL

- its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,  
 10 diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula VI with a compound of Formula XXXIX



to yield a compound of Formula XL.

95. A compound of claim 1, wherein

$R_1$  is hydrogen;

5  $R_2$  is ;

$R_3$  is  $-\text{OH}$ ;

$R_4$  is  $-\text{C}(=\text{O})R_z$ ;

$R_5$  is hydrogen;

$R_6$  is hydrogen; and

10  $m$  is 0.

96. The compound of claim 95, wherein  $R_z$  is  $-\text{NH}-(\text{CH}_2)_{0-3}$ -aryl,  $-\text{NH}-(\text{CH}_2)_{0-2}$ -substituted aryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -cycloalkyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -heteroaryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted cycloalkyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted heteroaryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl, N-containing heterocyclyl, substituted N-containing heterocyclyl, NH-alkyl, NH-substituted alkyl and  $\text{NH}_2$ .

15


97. The compound of claim 95, wherein  $W$  is H, OH,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -aryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -heteroaryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -heterosryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{O}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $-\text{O}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl,  $\text{O}-(\text{CH}_2)_{0-3}$ -alkynyl,  $\text{O}-(\text{CH}_2)_{0-3}$ -alkenyl, or halogen.

20



98. A compound of claim 1, wherein

$R_1$  is hydrogen;

$R_2$  is ;

$R_3$  is  $-OR_m$ ;

5  $R_5$  is hydrogen;

$R_6$  is hydrogen; and

$m$  is 0.

99. The compound of claim 98, wherein

10  $R_4$  is carboxyl,  $C_{1-4}$  alkyl ester, hydroxyl methyl,  $CH_2OCH_2-C_6H_5$ , or  $CH_2OCH_3$ .

100. The compound of claim 98, where  $R_m$  is hydrogen or  $C_1-C_5$  alkyl.

101. The compound of claim 98, herein  $W$  is H, OH,  $NHCO-(CH_2)_{0-3}$ -aryl,  $NHCO-(CH_2)_{0-3}$ -substituted aryl,  $NHCO-(CH_2)_{0-3}$ -heteroaryl,  $NHCO-(CH_2)_{0-3}$ -substituted aryl,  $OCO-(CH_2)_{0-3}$ -aryl,  $OCO-(CH_2)_{0-3}$ -substituted aryl,  $OCO-(CH_2)_{0-3}$ -heterosryl,  $OCO-$   
15  $(CH_2)_{0-3}$ -substituted aryl,  $O-(CH_2)_{0-3}$ -heterocyclyl,  $-O-(CH_2)_{0-3}$ -substituted heterocyclyl,  $NHCO-(CH_2)_{0-3}$ -heterocyclyl,  $NHCO-(CH_2)_{0-3}$ -substituted heterocyclyl,  $O-(CH_2)_{0-3}$ -alkynyl,  $O-(CH_2)_{0-3}$ -alkenyl, or halogen.

102. A compound of claim 1, wherein

20  $R_1$  is hydrogen or  $C_{1-5}$  alkyl;

$R_2$  is OH, or  $NH_2$ ;

$R_5$  is hydrogen;

$R_6$  is hydrogen; and

$m$  is 0.

103. The compound of claim 102, wherein

25  $R_4$  is  $CONH$ -aryl,  $CONH$ -substituted aryl, or  $(CH_2)_{1-3}-O-CH_3$ .